论文部分内容阅读
目的:分析左氧氟沙星、雷贝拉唑和阿莫西林三联疗法治疗幽门螺杆菌的疗效。方法:临床研究资料来源于我院2013年6月至2015年10月收治的幽门螺杆菌阳性消化性溃疡患者80例,根据随机方式将其进行分组。三联I组以克拉霉素、奥美拉唑和阿莫西林三联疗法治疗,三联II组以左氧氟沙星、雷贝拉唑和阿莫西林三联疗法治疗。对两组患者HP根除率、溃疡愈合率、副作用发生率。结果:三联II组患者HP根除率、溃疡愈合率均高于三联I组,P<0.05。而两组的副作用发生率无显著差异,P>0.05。结论:左氧氟沙星、雷贝拉唑和阿莫西林三联疗法治疗幽门螺杆菌的疗效确切,可有效根除幽门螺杆菌,促进溃疡愈合,且作用安全,值得推广。
Objective: To analyze the efficacy of levofloxacin, rabeprazole and amoxicillin triple therapy in the treatment of Helicobacter pylori. Methods: The data of clinical research were from 80 patients with H.pylori-positive peptic ulcer admitted in our hospital from June 2013 to October 2015. They were divided according to the random way. The triple I group was treated with triple therapy of clarithromycin, omeprazole and amoxicillin, while the triple combined group II was treated with levofloxacin, rabeprazole and amoxicillin triple therapy. The two groups of patients with HP eradication rate, healing rate of ulcers, the incidence of side effects. Results: The eradication rate and healing rate of ulcer in triple combined group II patients were higher than those in triple combined group I (P <0.05). There was no significant difference in the incidence of side effects between the two groups (P> 0.05). Conclusion: Levofloxacin, rabeprazole and amoxicillin triple therapy for the treatment of Helicobacter pylori is effective and can effectively eradicate Helicobacter pylori and promote ulcer healing, and its role is safe and worthy of promotion.